Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

Benzinga · 3d ago
Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Neutral rating.